Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia

Bone Marrow Transplantation

Volumn 21, Issue 11, 1998, Pages 1079-1083

  Hirabayashi, N ^a   Goto, S ^a   Ishii, M ^a   Yuge, M ^a   Mitsuma, A ^a   Noda, N ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Bone marrow transplantation; Busulfan with cyclophosphamide and total body irradiation (BU + CY + TBI); Myeloid leukemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

EID: 0031803440     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701244     Document Type: Article

References (21)

1. Blume KG. Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide vs busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a South West Oncology Group Study. Blood 1993: 81: 2187-2193.
2. Bearman SI. Clift RA, Appelbaum FR et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988: 6: 1562-1568.
3. Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. New Engl J Med 1975; 292: 832-843 and 895-902.
4. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute non-lymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
5. Tutschka PJ, Copelan EA. Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
6. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
7. Kanfer EJ, Buckner CD, Fefer A et al. Allogeneic and syngeneic transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation. Bone Marrow Transplant 1987; 1: 339-346.
8. Petersen FB, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. Bone Marrow Transplant 1989; 4: 617-623.
9. Lynch MHE, Petersen FB. Appelbaum FR et al. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies. Bone Marrow Transplant 1995; 15: 59-64.
10. Demirer T, Buckner CD, Appelbaum FR et al Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on target plasma levels. Bone Marrow Transplant 1996; 17: 341-346.
11. Hirabayashi N, Tobita T, Watanabe T et al. Busulfan. cyclophosphamide and total body irradiation as a conditioning regimen for allogeneic marrow transplantation in patients with advanced leukemias. Exp Hematol 1990; 18: 664 (Abstr. 436).
12. Hirabayashi N. Busulfan. cyclophosphamide and total body irradiation as a conditioning regimen for allogeneic marrow transplantation in patients with advanced leukemia. Transplantation Now 1991; 4 (Suppl. 1): 86-89.
13. Mehta J, Powles R, Treleaven J et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996: 18: 741-746.
14. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17 (Suppl. 3): S1-S3.
15. Bortin MM. Horowitz MM, Rowlings PA et al. 1993 progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97-104.
16. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996; 17 (Suppl. 3): S7-S9.
17. Galimberti M. Polchi P, Lucarelli G et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide. Bone Marrow Transplant 1994; 13: 577-581.
18. Keating S. Suciu S, de Witte T et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. Bone Marrow Transplant 1996; 17: 993-1001.
19. Bandini G, Belardinelli A, Rosti G et al. Toxicity of high-dose busulfan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with hematological malignancies. Bone Marrow Transplant 1994; 13: 577-581.
20. Labor B. Masszi T, Morabito F et al. Allogeneic bone marrow transplantation for acute leukemia - IGCI experience. International Group For Chemo-Immunotherapy. Bone Marrow-Transplant 1996; 17: 1009-1012.
21. Kumar M, Saleh A, Rao PV et al. Toxicity associated with high-dose cytosine arabinoside and total body irradiation as conditioning for allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 1061-1064.